India’s Natco Joins the March to China’s Market by Indian Pharmas

India’s Natco Joins the March to China’s Market by Indian Pharmas

India’s Natco Pharma, a company that specializes in complex generics, plans to build up its business in China, taking advantage of China’s speeded-up approval process to register products that are already approved elsewhere. Natco has...

Read more
Nanjing Frontier Biotech Plans $285 Million IPO on Shanghai STAR Exchange

Nanjing Frontier Biotech Plans $285 Million IPO on Shanghai STAR Exchange

Nanjing Frontier Biotechnologies was approved to stage a $285 million IPO on the Shanghai STAR Exchange. Frontier has a China approved treatment for HIV, and it is developing another HIV treatment that it in-licensed from the Rockefeller...

Read more
Beijing Baicare Closes $9 Million Round for Clinical Diagnostic Devices

Beijing Baicare Closes $9 Million Round for Clinical Diagnostic Devices

Beijing Baicare Biotech closed a $9 million B financing that was led by Sinopharm Capital and included the company’s existing shareholders. Formed in 2013, Baicare makes automated nucleic acid detection devices for clinical use using...

Read more
Brain Cancer Patients Display Decreasing Tumor Biomarkers After Treatment with Novel Immunotherapy in AIVITA Biomedical’s Phase 2 Clinical Trial

Brain Cancer Patients Display Decreasing Tumor Biomarkers After Treatment with Novel Immunotherapy in AIVITA Biomedical’s Phase 2 Clinical Trial

AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today updated clinical data from its ongoing glioblastoma Phase 2 clinical trial, investigating AIVITA’s platform immunotherapy...

Read more
FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs

FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs

The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...

Read more
Qiyu Biotech of Shanghai Completes A Funding Round for Novel Biologics

Qiyu Biotech of Shanghai Completes A Funding Round for Novel Biologics

Qiyu Biotechnology, a Shanghai startup located in Zhangjiang Hi-Tech Park, completed a Series A round that raised “tens of millions of RMB” from Jundu Investment and Wosheng Capital. This proceeds are earmarked to support the...

Read more
Bio-Thera Starts China Trials of a Third Arthritis Biosimilar

Bio-Thera Starts China Trials of a Third Arthritis Biosimilar

Bio-Thera Solutions of Guangzhou has begun a China Phase I trial to examine the pharmacokinetics and safety of its BAT2506, a proposed biosimilar to Simponi® (golimumab), a Janssen treatment for arthritis/ulcerative colitis. The comparison trial...

Read more
CStone Starts China Arm of Global RET Inhibitor Phase I Trial

CStone Starts China Arm of Global RET Inhibitor Phase I Trial

CStone, a Suzhou biopharma, has dosed the first patient in the China arm of a global Phase I registrational study of BLU-667, a RET-inhibitor, in patients with various solid tumor cancers. One year ago, CStone in-licensed greater China rights to...

Read more
Aslan Presents Progress Update on its Three Clinical Candidates

Aslan Presents Progress Update on its Three Clinical Candidates

Aslan Pharma of Singapore provided an update on the progress of its three clinical-stage oncology and immunology candidates: • The company signed up K-MASTER to run a 400 patient South Korean Phase Ib/II trial of its lead drug, varlitinib, in...

Read more
DelMar Reports Positive Phase II Data from China Trial of GBM Treatment

DelMar Reports Positive Phase II Data from China Trial of GBM Treatment

DelMar Pharma of Vancouver and Menlo Park reported early results from its China Phase II trial of VAL-083 as a first line treatment for glioblastoma multiforme. VAL-083 is being administered along with radiation to patients with newly-diagnosed...

Read more
Chipscreen Bio Climbs 367% on First Trading Day following Shanghai IPO

Chipscreen Bio Climbs 367% on First Trading Day following Shanghai IPO

China’s Chipscreen Bio gained a stunning 367% in its first trading session following its IPO on the Shanghai STAR exchange, giving the company a market cap of $4.2 billion, When the first 25 STAR Board IPOs hit the market last month, the...

Read more
Ascletis Opens Clinical Development Shanghai Center

Ascletis Opens Clinical Development Shanghai Center

Ascletis Pharma Inc.(1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today the opening of its...

Read more
Do NOT follow this link or you will be banned from the site!